Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data against one of the newer immuno-oncology targets. New targets and data for a bispecific mAb showed early promise at the meeting earlier this week.

In the biggest miss for Roche (SIX:ROG; OTCQX:RHHBY), data

Read the full 684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE